Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of leonurine and crystals thereof in preparation of medicine for resisting hyperhomocysteinemia

A technology of leonurine and application, which is applied in the field of preparing anti-hyperhomocysteinemia drugs to achieve the effect of reducing the incidence rate

Pending Publication Date: 2020-08-28
FUDAN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Studies have shown that hyperhomocysteinemia has become a risk factor for a variety of other diseases, including diabetes, Alzheimer's disease, pregnancy-induced hypertension, neonatal defects, and habitual abortion; currently there is no specific treatment for hyperhomocysteinemia medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of leonurine and crystals thereof in preparation of medicine for resisting hyperhomocysteinemia
  • Application of leonurine and crystals thereof in preparation of medicine for resisting hyperhomocysteinemia
  • Application of leonurine and crystals thereof in preparation of medicine for resisting hyperhomocysteinemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 In ApoE - / - To verify the effects of motherwortine and its A-type crystals on blood Hcy levels in the animal model of metabolic disorders fed with high-fat feed

[0048] Experimental methods include: ApoE - / - The mice were fed with normal feed in the SPF grade animal room until 6 weeks old, and then randomly divided into 5 groups according to the following grouping scheme for feeding and administration:

[0049] 1) Control group (ApoE - / - Mice were fed with normal feed, n=14), and triple-distilled water was administered orally (1 ml / kg body weight) once a day;

[0050] 2) Model solvent control group (ApoE - / - Mice, high-fat diet, n=16), triple distilled water gavage (1 ml / kg body weight) once a day;

[0051] 3) Leonurine A crystal low dose group (ApoE - / - Mice, high-fat feed, n=8), and once a day, the motherwortine type A crystal solution was administered orally (the drug dose was 10 mg / kg / day, and the drug concentration was 10 mg / ml);

[0052] 4) Medium...

Embodiment 2

[0057] Example 2 Detection of mouse plasma Hcy level by enzyme-linked immunosorbent assay

[0058] Experimental principle: The kit uses a competitive method to detect the content of Hcy in the sample; add the sample to the antibody-coated enzyme-labeled well, then add the biotin-labeled recognition antigen, and incubate at 37°C for 30 minutes. Antibodies compete for binding to form immune complexes, wash with PBST to remove unbound biotin antigen, then add avidin-HRP, incubate at 37°C for 30min, avidin-HRP binds to biotin antigen, and the bound HRP is washed Catalyze TMB (tetramethylbenzidine) into blue, and then turn into yellow under the action of acid, with an absorption peak at 450nm wavelength, and the absorbance value is negatively correlated with the concentration of antigen in the sample;

[0059] Operation steps: Please equilibrate the kit at room temperature for half an hour before use;

[0060] Blank well: no sample is added, only chromogen A, B and stop solution a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of modern pharmacy of traditional Chinese medicines, and relates to a Chinese herbal medicine leonurus extract and application thereof in pharmacy, in particular toapplication of a medicinal crystal form of leonurine of the Chinese herbal medicine leonurus extract in preparation of medicines, wherein the chemical name of the leonurine is 3, 5-dimethoxy-4-hydroxy-benzoic acid (4-guanidyl)-1-butyl ester. According to the invention, the leonurine is prepared into a hydrate crystal form, and experiments prove that the leonurine has the effect of reducing homocysteine (Hcy). The leonurine and the crystal form thereof disclosed by the invention can be used for preparing medicines for resisting various diseases caused by high Hcy, wherein the diseases comprisecardiovascular and cerebrovascular diseases, senile dementia, cerebral apoplexy, venous embolism, newborn defects and habitual abortion. The medicines are especially suitable for early intervention ofthe above diseases, have the effect of reducing the incidence of early cardiovascular risk factors and other related diseases, and can reduce the disease state where other specific risk factors suchas triglyceride, cholesterol and low-density lipoprotein are not increased but are likely to cause cardiovascular and cerebrovascular diseases.

Description

technical field [0001] The invention belongs to the field of modern pharmaceuticals of traditional Chinese medicine, and relates to a new application of a crystal of motherurine extracted from Chinese herbal medicine Leonurus in pharmacy, especially the application in preparation of anti-hyperhomocysteine ​​(Hcy) blood medicine. The anti-hyper-Hcy blood drug of the present invention is suitable for preventing and treating diseases caused by Hcy, including cardiovascular and cerebrovascular diseases, Alzheimer's disease, cerebral apoplexy, venous thrombosis, neonatal defects and habitual abortion. Background technique [0002] The prior art discloses that homocysteine ​​(Homocysteine, Hcy) is a sulfur-containing amino acid, and is an important intermediate product produced during the metabolism of methionine, which is produced by demethylation of methionine. Under normal circumstances, the concentration of blood Hcy in the body is maintained at a low level, but genetic factor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P9/00A61P9/10A61P3/10A61P9/12A61P15/00A61P15/06A61P7/02C07C279/08
CPCA61K31/235A61P9/00A61P9/10A61P3/10A61P9/12A61P15/00A61P15/06A61P7/02C07C277/08C07C279/08C07B2200/13
Inventor 朱依纯朱依谆宁可慕雪盼陈莹
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com